尽管林业发展局的核准有限,但在越来越多的支持和VA研究下,迷魂药疗法显示出对老兵心理健康的希望。 Psychedelic therapies show promise for veteran mental health, with growing support and VA studies despite limited FDA approvals.

美国退伍军人的创伤后精神紧张症、抑郁症和焦虑症可能得到治疗,尽管除氯胺酮鼻涕喷剂外,林业发展局的核准有限,但是在临床试验中,pilocybin、MDMA和ibogaine显示出希望。 Psychedelic-assisted therapies are gaining traction as a potential treatment for PTSD, depression, and anxiety in U.S. veterans, with psilocybin, MDMA, and ibogaine showing promise in clinical trials despite limited FDA approvals beyond ketamine nasal spray. 受害者协会目前正在进行关于MDMA和psilocybin的研究,而DAV等倡导团体则在推动扩大研究和今后获得治疗的机会,理由是传统治疗的失败率很高。 The VA is now conducting studies on MDMA and psilocybin, while advocacy groups like DAV are pushing for expanded research and future access, citing high failure rates with traditional treatments. 在其2025年国民大会上,发展合作署主办了一次圆桌会议,推进以退伍军人为中心的政策,反映出各州和医疗界日益增强的势头,探讨这些疗法,作为解决退伍军人长期面临的心理健康挑战的变革性备选方案。 At its 2025 National Convention, DAV hosted a roundtable to advance veteran-centered policy, reflecting growing momentum across states and the medical community to explore these therapies as a transformative option for addressing the persistent mental health challenges faced by veterans.